Program
177Lu-DFC413
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Novartis.
Furthest: phase 1, since Nov 21, 20251 company-led study, 1 open or runningNext primary completion: May 9, 2029 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 11 open or running | phase 1since Nov 21, 2025 | Nov 21, 2025 | May 9, 2029phase 1 · NCT07261631 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 21, 2025First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07261631 · 180 planned · United States, Canada, Denmark and more
Ahead
- May 9, 2029Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07261631
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07261631Carcinoma, Non-Small-Cell Lung · United States, Canada, Denmark and more | 1 | Recruiting | May 9, 2029 | 180 |
How it is read
Names in the registry
- “177Lu-DFC413”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.